Sana gets a com­peti­tor as Take­da, 5AM pour $170M in­to a Fred Hutch pi­o­neer's quest to un­seat CAR-T, ex vi­vo gene ...

5 years ago
Financing

SR One re­cruits an IPO vet and sea­soned ops chief for the ven­ture team. And they have some prac­ti­cal ad­vice for you

5 years ago
People

Af­ter purg­ing its own can­di­dates, Mer­ck says it's ready to as­sist in Covid-19 vac­cine pro­duc­tion

5 years ago
Coronavirus

As US da­ta for Covid-19 vac­cine loom, As­traZeneca cleans house and scraps sev­er­al asth­ma, can­cer drugs from pipeline

5 years ago
R&D

As­traZeneca looks to re­bound from pro­duc­tion de­lays for its Covid-19 vac­cine with new fill-fin­ish deal

5 years ago
Outsourcing
Coronavirus

Ab­b­Vie adds to the Botox war chest with a 12th FDA ap­proval — but com­pe­ti­tion is fast ap­proach­ing

5 years ago
FDA+

Mi­rati and MD An­der­son team up on KRAS; Sanofi inks deal with a Har­vard spin­out for oral bi­o­log­ics

5 years ago
News Briefing

Covid-19 roundup: South Africa con­sid­ers sell­ing or swap­ping As­traZeneca shots; Chi­na calls for WHO probe in US

5 years ago
Coronavirus

Eli Cas­din and Ic­ahn pro­tégé find a home for their $450M SPAC, merg­ing with Se­ma4

5 years ago
Financing

Dan O’Day’s $5B deal with Gala­pa­gos im­plodes as PhI­II tri­als col­lapse

5 years ago
R&D

Ab­b­Vie taps Jen­nifer Doud­na start­up for li­cens­ing deal worth up to $300M for 2 'off-the-shelf' CRISPR-edit­ed CAR-Ts

5 years ago
Deals
Cell/Gene Tx

On the hunt for a bet­ter an­ti­body, BigHat Bio­sciences de­buts with $19M Se­ries A to scale its 'wet lab' AI plat­form

5 years ago
Financing
AI

With a ros­ter of gene ther­a­py vets, For­bion makes a bet on 'rel­a­tive­ly emp­ty space' of vec­tor­ized an­ti­bod­ies

5 years ago
Startups
Cell/Gene Tx

A year af­ter FTC nixed Il­lu­mi­na buy­out, Soft­Bank bets $900M on PacBio's new vi­sion

5 years ago
Financing

'In­dus­tri­al­iz­ing the pro­duc­tion of cell­s': An­oth­er iP­SC play­er joins the quest for off-the-shelf cell ther­a­pies

5 years ago
Financing
Cell/Gene Tx

With 'rapid' progress of pe­di­atric brain can­cer treat­ment, Day One sees broad ex­cite­ment in new crossover round

5 years ago
Financing

Eli Lil­ly racks up EUA for an­ti­body cock­tail — but the big­ger chal­lenge is still ahead

5 years ago
FDA+
Coronavirus

With Lib­tay­o's sec­ond ap­proval, Re­gen­eron digs deep­er in­to PD-1 der­ma­to-on­col­o­gy niche

5 years ago
FDA+

FDA pan­el ad­mon­ish­es Mer­ck with a gen­tle — and rare — slap­down for rush­ing its pitch on an ac­cel­er­at­ed OK for ...

5 years ago
R&D

J&J's Er­lea­da/Zyti­ga com­bo hits PhI­II end­point — but what about OS?; Tar­go­v­ax los­es prostate can­cer part­ner af­ter ...

5 years ago
News Briefing

Nau­tilus set to go pub­lic in re­verse merg­er with Per­cep­tive SPAC, aims to test pro­teomics plat­form with big-name ...

5 years ago
Financing

UP­DAT­ED — Covid-19 roundup: WHO all but con­firms virus not man-made; Neu­roRx, Re­lief say they don't know if IV ...

5 years ago
Coronavirus

One of the gi­ant vac­cine play­ers push­es back against a ‘fun­da­men­tal shift’ spurred by mR­NA. But is the CEO just ...

5 years ago
Bioregnum
Coronavirus

Months af­ter shock­ing house ar­rest, Leg­end co-founder Frank Zhang is out on bail — though the CAR-T play­er has ...

5 years ago
People
China
First page Previous page 736737738739740741742 Next page Last page
A service from the Financial Times